Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Research Report 2026(Status and Outlook)
The global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size was estimated at USD 2500.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
This report offers a comprehensive and in-depth analysis of the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market.
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
- AbaStar MDx
- Abbott Laboratories
- Abiant
- Acumen Pharmaceuticals
- Alseres Pharmaceuticals
- Athena Diagnostics
- Banyan Biomarkers
- Bio-Rad Laboratories
- Diagenic ASA
- Immunarray Pvt
- Myriad RBM
- Proteome Sciences
- ProteoSys AG
- Psynova Neurotech
- Qiagen
- Quanterix Corporation
- Thermo Fisher Scientific
Market Segmentation (by Type)
- Genome
- Proteome
Market Segmentation (by Application)
- Hospital Laboratories
- Research Organizations
- Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
Overview of the regional outlook of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
1.2 Key Market Segments
1.2.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Type
1.2.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Manufacturers (2020-2025)
3.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation and Trends
3.8.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES INDUSTRY CHAIN ANALYSIS
4.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
5.7 ESG Ratings of Leading Companies
6 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (2020-2025)
6.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Type (2020-2025)
7 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Application (2020-2025)
7.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Application (2020-2025)
7.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
8 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SALES BY REGION
8.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region
8.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.3 North America
8.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.4.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.5.2 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.6.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.7.2 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET PRODUCTION BY REGION
9.1 Global Production of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Region(2020-2025)
9.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
9.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.4.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.5.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.5.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.6.1 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.6.2 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.7.1 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.7.2 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 AbaStar MDx
10.1.1 AbaStar MDx Basic Information
10.1.2 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.1.4 AbaStar MDx Business Overview
10.1.5 AbaStar MDx SWOT Analysis
10.1.6 AbaStar MDx Recent Developments
10.2 Abbott Laboratories
10.2.1 Abbott Laboratories Basic Information
10.2.2 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.2.4 Abbott Laboratories Business Overview
10.2.5 Abbott Laboratories SWOT Analysis
10.2.6 Abbott Laboratories Recent Developments
10.3 Abiant
10.3.1 Abiant Basic Information
10.3.2 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.3.4 Abiant Business Overview
10.3.5 Abiant SWOT Analysis
10.3.6 Abiant Recent Developments
10.4 Acumen Pharmaceuticals
10.4.1 Acumen Pharmaceuticals Basic Information
10.4.2 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.4.4 Acumen Pharmaceuticals Business Overview
10.4.5 Acumen Pharmaceuticals Recent Developments
10.5 Alseres Pharmaceuticals
10.5.1 Alseres Pharmaceuticals Basic Information
10.5.2 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.5.4 Alseres Pharmaceuticals Business Overview
10.5.5 Alseres Pharmaceuticals Recent Developments
10.6 Athena Diagnostics
10.6.1 Athena Diagnostics Basic Information
10.6.2 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.6.4 Athena Diagnostics Business Overview
10.6.5 Athena Diagnostics Recent Developments
10.7 Banyan Biomarkers
10.7.1 Banyan Biomarkers Basic Information
10.7.2 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.7.4 Banyan Biomarkers Business Overview
10.7.5 Banyan Biomarkers Recent Developments
10.8 Bio-Rad Laboratories
10.8.1 Bio-Rad Laboratories Basic Information
10.8.2 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.8.4 Bio-Rad Laboratories Business Overview
10.8.5 Bio-Rad Laboratories Recent Developments
10.9 Diagenic ASA
10.9.1 Diagenic ASA Basic Information
10.9.2 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.9.4 Diagenic ASA Business Overview
10.9.5 Diagenic ASA Recent Developments
10.10 Immunarray Pvt
10.10.1 Immunarray Pvt Basic Information
10.10.2 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.10.4 Immunarray Pvt Business Overview
10.10.5 Immunarray Pvt Recent Developments
10.11 Myriad RBM
10.11.1 Myriad RBM Basic Information
10.11.2 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.11.4 Myriad RBM Business Overview
10.11.5 Myriad RBM Recent Developments
10.12 Proteome Sciences
10.12.1 Proteome Sciences Basic Information
10.12.2 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.12.4 Proteome Sciences Business Overview
10.12.5 Proteome Sciences Recent Developments
10.13 ProteoSys AG
10.13.1 ProteoSys AG Basic Information
10.13.2 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.13.4 ProteoSys AG Business Overview
10.13.5 ProteoSys AG Recent Developments
10.14 Psynova Neurotech
10.14.1 Psynova Neurotech Basic Information
10.14.2 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.14.4 Psynova Neurotech Business Overview
10.14.5 Psynova Neurotech Recent Developments
10.15 Qiagen
10.15.1 Qiagen Basic Information
10.15.2 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.15.4 Qiagen Business Overview
10.15.5 Qiagen Recent Developments
10.16 Quanterix Corporation
10.16.1 Quanterix Corporation Basic Information
10.16.2 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.16.4 Quanterix Corporation Business Overview
10.16.5 Quanterix Corporation Recent Developments
10.17 Thermo Fisher Scientific
10.17.1 Thermo Fisher Scientific Basic Information
10.17.2 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.17.4 Thermo Fisher Scientific Business Overview
10.17.5 Thermo Fisher Scientific Recent Developments
11 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET FORECAST BY REGION
11.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast
11.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.3 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region
11.2.4 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2035)
12.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2035)
12.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Application (2026-2035)
12.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application
12.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
1.2 Key Market Segments
1.2.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Type
1.2.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Manufacturers (2020-2025)
3.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation and Trends
3.8.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES INDUSTRY CHAIN ANALYSIS
4.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
5.7 ESG Ratings of Leading Companies
6 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (2020-2025)
6.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Type (2020-2025)
7 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Application (2020-2025)
7.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Application (2020-2025)
7.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
8 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET SALES BY REGION
8.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region
8.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.3 North America
8.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.4.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.5.2 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
8.6.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
8.7.2 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET PRODUCTION BY REGION
9.1 Global Production of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Region(2020-2025)
9.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
9.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.4.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
9.5.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.5.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.6.1 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.6.2 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
9.7.1 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
9.7.2 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 AbaStar MDx
10.1.1 AbaStar MDx Basic Information
10.1.2 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.1.4 AbaStar MDx Business Overview
10.1.5 AbaStar MDx SWOT Analysis
10.1.6 AbaStar MDx Recent Developments
10.2 Abbott Laboratories
10.2.1 Abbott Laboratories Basic Information
10.2.2 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.2.4 Abbott Laboratories Business Overview
10.2.5 Abbott Laboratories SWOT Analysis
10.2.6 Abbott Laboratories Recent Developments
10.3 Abiant
10.3.1 Abiant Basic Information
10.3.2 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.3.4 Abiant Business Overview
10.3.5 Abiant SWOT Analysis
10.3.6 Abiant Recent Developments
10.4 Acumen Pharmaceuticals
10.4.1 Acumen Pharmaceuticals Basic Information
10.4.2 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.4.4 Acumen Pharmaceuticals Business Overview
10.4.5 Acumen Pharmaceuticals Recent Developments
10.5 Alseres Pharmaceuticals
10.5.1 Alseres Pharmaceuticals Basic Information
10.5.2 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.5.4 Alseres Pharmaceuticals Business Overview
10.5.5 Alseres Pharmaceuticals Recent Developments
10.6 Athena Diagnostics
10.6.1 Athena Diagnostics Basic Information
10.6.2 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.6.4 Athena Diagnostics Business Overview
10.6.5 Athena Diagnostics Recent Developments
10.7 Banyan Biomarkers
10.7.1 Banyan Biomarkers Basic Information
10.7.2 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.7.4 Banyan Biomarkers Business Overview
10.7.5 Banyan Biomarkers Recent Developments
10.8 Bio-Rad Laboratories
10.8.1 Bio-Rad Laboratories Basic Information
10.8.2 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.8.4 Bio-Rad Laboratories Business Overview
10.8.5 Bio-Rad Laboratories Recent Developments
10.9 Diagenic ASA
10.9.1 Diagenic ASA Basic Information
10.9.2 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.9.4 Diagenic ASA Business Overview
10.9.5 Diagenic ASA Recent Developments
10.10 Immunarray Pvt
10.10.1 Immunarray Pvt Basic Information
10.10.2 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.10.4 Immunarray Pvt Business Overview
10.10.5 Immunarray Pvt Recent Developments
10.11 Myriad RBM
10.11.1 Myriad RBM Basic Information
10.11.2 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.11.4 Myriad RBM Business Overview
10.11.5 Myriad RBM Recent Developments
10.12 Proteome Sciences
10.12.1 Proteome Sciences Basic Information
10.12.2 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.12.4 Proteome Sciences Business Overview
10.12.5 Proteome Sciences Recent Developments
10.13 ProteoSys AG
10.13.1 ProteoSys AG Basic Information
10.13.2 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.13.4 ProteoSys AG Business Overview
10.13.5 ProteoSys AG Recent Developments
10.14 Psynova Neurotech
10.14.1 Psynova Neurotech Basic Information
10.14.2 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.14.4 Psynova Neurotech Business Overview
10.14.5 Psynova Neurotech Recent Developments
10.15 Qiagen
10.15.1 Qiagen Basic Information
10.15.2 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.15.4 Qiagen Business Overview
10.15.5 Qiagen Recent Developments
10.16 Quanterix Corporation
10.16.1 Quanterix Corporation Basic Information
10.16.2 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.16.4 Quanterix Corporation Business Overview
10.16.5 Quanterix Corporation Recent Developments
10.17 Thermo Fisher Scientific
10.17.1 Thermo Fisher Scientific Basic Information
10.17.2 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
10.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
10.17.4 Thermo Fisher Scientific Business Overview
10.17.5 Thermo Fisher Scientific Recent Developments
11 NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES MARKET FORECAST BY REGION
11.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast
11.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.3 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region
11.2.4 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2035)
12.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2035)
12.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Application (2026-2035)
12.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application
12.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (M USD)
Table 4. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application
Table 5. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Comparison by Region (M USD)
Table 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases as of 2025)
Table 11. Global Market Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Type (K Units)
Table 27. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (M USD)
Table 28. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Type (2020-2025)
Table 29. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
Table 30. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Type (2020-2025)
Table 31. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Type (2020-2025)
Table 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (USD/Unit) by Type (2020-2025)
Table 33. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Application
Table 34. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application
Table 35. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Application (2020-2025) & (K Units)
Table 36. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2025)
Table 37. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application (2020-2025)
Table 39. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
Table 40. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 41. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2025)
Table 42. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025)
Table 44. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 45. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 47. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 51. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) by Region(2020-2025)
Table 55. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
Table 57. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. AbaStar MDx Basic Information
Table 63. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 64. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. AbaStar MDx Business Overview
Table 66. AbaStar MDx SWOT Analysis
Table 67. AbaStar MDx Recent Developments
Table 68. Abbott Laboratories Basic Information
Table 69. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 70. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Abbott Laboratories Business Overview
Table 72. Abbott Laboratories SWOT Analysis
Table 73. Abbott Laboratories Recent Developments
Table 74. Abiant Basic Information
Table 75. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 76. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Abiant Business Overview
Table 78. Abiant SWOT Analysis
Table 79. Abiant Recent Developments
Table 80. Acumen Pharmaceuticals Basic Information
Table 81. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 82. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Acumen Pharmaceuticals Business Overview
Table 84. Acumen Pharmaceuticals Recent Developments
Table 85. Alseres Pharmaceuticals Basic Information
Table 86. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 87. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Alseres Pharmaceuticals Business Overview
Table 89. Alseres Pharmaceuticals Recent Developments
Table 90. Athena Diagnostics Basic Information
Table 91. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 92. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Athena Diagnostics Business Overview
Table 94. Athena Diagnostics Recent Developments
Table 95. Banyan Biomarkers Basic Information
Table 96. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 97. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Banyan Biomarkers Business Overview
Table 99. Banyan Biomarkers Recent Developments
Table 100. Bio-Rad Laboratories Basic Information
Table 101. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 102. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Bio-Rad Laboratories Business Overview
Table 104. Bio-Rad Laboratories Recent Developments
Table 105. Diagenic ASA Basic Information
Table 106. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 107. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Diagenic ASA Business Overview
Table 109. Diagenic ASA Recent Developments
Table 110. Immunarray Pvt Basic Information
Table 111. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 112. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Immunarray Pvt Business Overview
Table 114. Immunarray Pvt Recent Developments
Table 115. Myriad RBM Basic Information
Table 116. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 117. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Myriad RBM Business Overview
Table 119. Myriad RBM Recent Developments
Table 120. Proteome Sciences Basic Information
Table 121. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 122. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Proteome Sciences Business Overview
Table 124. Proteome Sciences Recent Developments
Table 125. ProteoSys AG Basic Information
Table 126. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 127. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. ProteoSys AG Business Overview
Table 129. ProteoSys AG Recent Developments
Table 130. Psynova Neurotech Basic Information
Table 131. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 132. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Psynova Neurotech Business Overview
Table 134. Psynova Neurotech Recent Developments
Table 135. Qiagen Basic Information
Table 136. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 137. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Qiagen Business Overview
Table 139. Qiagen Recent Developments
Table 140. Quanterix Corporation Basic Information
Table 141. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 142. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Quanterix Corporation Business Overview
Table 144. Quanterix Corporation Recent Developments
Table 145. Thermo Fisher Scientific Basic Information
Table 146. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 147. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. Thermo Fisher Scientific Business Overview
Table 149. Thermo Fisher Scientific Recent Developments
Table 150. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Region (2026-2035) & (K Units)
Table 151. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 153. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 155. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Region (2026-2035) & (K Units)
Table 157. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 159. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Type (2026-2035) & (K Units)
Table 163. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price Forecast by Type (2026-2035) & (USD/Unit)
Table 165. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application (2026-2035)
Table 166. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (M USD)
Table 4. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application
Table 5. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Comparison by Region (M USD)
Table 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases as of 2025)
Table 11. Global Market Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Type (K Units)
Table 27. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Type (M USD)
Table 28. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Type (2020-2025)
Table 29. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
Table 30. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Type (2020-2025)
Table 31. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Type (2020-2025)
Table 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (USD/Unit) by Type (2020-2025)
Table 33. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Application
Table 34. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application
Table 35. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Application (2020-2025) & (K Units)
Table 36. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2025)
Table 37. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application (2020-2025)
Table 39. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
Table 40. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 41. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2025)
Table 42. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025)
Table 44. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 45. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 47. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
Table 51. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) by Region(2020-2025)
Table 55. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
Table 57. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. AbaStar MDx Basic Information
Table 63. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 64. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. AbaStar MDx Business Overview
Table 66. AbaStar MDx SWOT Analysis
Table 67. AbaStar MDx Recent Developments
Table 68. Abbott Laboratories Basic Information
Table 69. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 70. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Abbott Laboratories Business Overview
Table 72. Abbott Laboratories SWOT Analysis
Table 73. Abbott Laboratories Recent Developments
Table 74. Abiant Basic Information
Table 75. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 76. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Abiant Business Overview
Table 78. Abiant SWOT Analysis
Table 79. Abiant Recent Developments
Table 80. Acumen Pharmaceuticals Basic Information
Table 81. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 82. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Acumen Pharmaceuticals Business Overview
Table 84. Acumen Pharmaceuticals Recent Developments
Table 85. Alseres Pharmaceuticals Basic Information
Table 86. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 87. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Alseres Pharmaceuticals Business Overview
Table 89. Alseres Pharmaceuticals Recent Developments
Table 90. Athena Diagnostics Basic Information
Table 91. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 92. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Athena Diagnostics Business Overview
Table 94. Athena Diagnostics Recent Developments
Table 95. Banyan Biomarkers Basic Information
Table 96. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 97. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Banyan Biomarkers Business Overview
Table 99. Banyan Biomarkers Recent Developments
Table 100. Bio-Rad Laboratories Basic Information
Table 101. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 102. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Bio-Rad Laboratories Business Overview
Table 104. Bio-Rad Laboratories Recent Developments
Table 105. Diagenic ASA Basic Information
Table 106. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 107. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Diagenic ASA Business Overview
Table 109. Diagenic ASA Recent Developments
Table 110. Immunarray Pvt Basic Information
Table 111. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 112. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Immunarray Pvt Business Overview
Table 114. Immunarray Pvt Recent Developments
Table 115. Myriad RBM Basic Information
Table 116. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 117. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Myriad RBM Business Overview
Table 119. Myriad RBM Recent Developments
Table 120. Proteome Sciences Basic Information
Table 121. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 122. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Proteome Sciences Business Overview
Table 124. Proteome Sciences Recent Developments
Table 125. ProteoSys AG Basic Information
Table 126. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 127. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. ProteoSys AG Business Overview
Table 129. ProteoSys AG Recent Developments
Table 130. Psynova Neurotech Basic Information
Table 131. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 132. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Psynova Neurotech Business Overview
Table 134. Psynova Neurotech Recent Developments
Table 135. Qiagen Basic Information
Table 136. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 137. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Qiagen Business Overview
Table 139. Qiagen Recent Developments
Table 140. Quanterix Corporation Basic Information
Table 141. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 142. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 143. Quanterix Corporation Business Overview
Table 144. Quanterix Corporation Recent Developments
Table 145. Thermo Fisher Scientific Basic Information
Table 146. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
Table 147. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 148. Thermo Fisher Scientific Business Overview
Table 149. Thermo Fisher Scientific Recent Developments
Table 150. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Region (2026-2035) & (K Units)
Table 151. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 153. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 155. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Region (2026-2035) & (K Units)
Table 157. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (K Units)
Table 159. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Type (2026-2035) & (K Units)
Table 163. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price Forecast by Type (2026-2035) & (USD/Unit)
Table 165. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application (2026-2035)
Table 166. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD), 2025-2035
Figure 5. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) (2020-2035)
Figure 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
Figure 13. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Share by Manufacturers in 2025
Figure 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers in 2025
Figure 15. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue in 2025
Figure 18. Industry Chain Map of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 19. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market PEST Analysis
Figure 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Type
Figure 27. Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2025)
Figure 28. Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type in 2025
Figure 29. Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2025)
Figure 30. Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application
Figure 33. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2025)
Figure 34. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application in 2025
Figure 35. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application (2020-2025)
Figure 36. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application in 2025
Figure 37. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2025)
Figure 39. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025)
Figure 40. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 43. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 45. U.S. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 53. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 55. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region in 2024
Figure 68. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 79. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 80. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (M USD)
Figure 81. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 82. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region in 2024
Figure 92. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Market Share by Region (2020-2025)
Figure 103. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 106. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share Forecast by Type (2026-2035)
Figure 111. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Application (2026-2035)
Figure 112. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD), 2025-2035
Figure 5. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) (2020-2035)
Figure 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
Figure 13. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Share by Manufacturers in 2025
Figure 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers in 2025
Figure 15. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue in 2025
Figure 18. Industry Chain Map of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 19. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market PEST Analysis
Figure 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Type
Figure 27. Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2025)
Figure 28. Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type in 2025
Figure 29. Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2025)
Figure 30. Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application
Figure 33. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2025)
Figure 34. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application in 2025
Figure 35. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application (2020-2025)
Figure 36. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application in 2025
Figure 37. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2025)
Figure 39. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (2020-2025)
Figure 40. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 43. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 45. U.S. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 53. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 55. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region in 2024
Figure 68. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 79. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country in 2024
Figure 80. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (M USD)
Figure 81. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country in 2024
Figure 82. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region in 2024
Figure 92. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Market Share by Region (2020-2025)
Figure 103. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 106. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share Forecast by Type (2026-2035)
Figure 111. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Forecast by Application (2026-2035)
Figure 112. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share Forecast by Application (2026-2035)
